Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

@article{Lock2002GenemicroarrayAO,
  title={Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis},
  author={Christopher B. Lock and Guy Hermans and Rosetta Pedotti and Andrea Brendolan and Eric Schadt and Hideki Garren and Annette M Langer-Gould and Samuel Strober and Barbara Cannella and John D. Allard and Paul Klonowski and Angela Austin and Nagin Lad and Naftali Kaminski and Stephen J. Galli and Jorge R. Oksenberg and Cedric S Raine and Renu A. Heller and Lawrence Steinman},
  journal={Nature Medicine},
  year={2002},
  volume={8},
  pages={500-508}
}
Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and -17, interferon-γ and associated downstream pathways. Comparison of two poles of MS pathology—acute lesions with inflammation versus 'silent' lesions without inflammation—revealed differentially transcribed genes. Some products of these genes were chosen as targets for therapy of experimental autoimmune… 
Microarrays: Validation on target
  • M. Brazil
  • Biology
    Nature Reviews Drug Discovery
  • 2002
TLDR
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalitis, suggesting that chips constructed by this chemical approach could find broad application in glycobiology, from research to drug discovery and diagnostics.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis–Directed Therapeutics
TLDR
Results show that neurons and oligodendrocytes are highly sensitive to CNS-directed autoimmunity before the development of clinical symptoms and immunopathology and reveal a role for soluble TNF in mediating the earliest changes in gene expression.
Exploiting genotypic differences to identify genes important for EAE development
Blood transcriptional signatures of multiple sclerosis: Unique gene expression of disease activity
TLDR
It is indicated that gene expression patterns in PBMCs contain information about a remote‐target disease process that may be useful for diagnosis and future tailoring of therapeutic strategies for MS.
Animal models of multiple sclerosis—Potentials and limitations
Gene microarray analysis of multiple sclerosis lesions.
Transcriptomic Meta-Analysis of Multiple Sclerosis and Its Experimental Models
TLDR
A meta-analysis based on a simple comparison of DEGs is over-conservative and the more experimental GSEA approach identified both, a priori anticipated as well as promising new candidate pathways.
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets
TLDR
In vivo administration of hirudin or recombinant activated protein C reduced disease severity in experimental autoimmune encephalomyelitis and suppressed Th1 and Th17 cytokines in astrocytes and immune cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays
TLDR
Using cDNA microarray technology, experiments on MS tissue monitoring the expression pattern of over 5,000 genes were performed and 60 differentially expressed genes were identified, including the Duffy chemokine receptor, interferon regulatory factor‐2, and tumor necrosis factor alpha receptor‐2 among others.
Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays.
TLDR
Using cDNA microarray technology, experiments on MS tissue monitoring the expression pattern of over 5,000 genes were performed and two differentially expressed genes were identified, including the Duffy chemokine receptor, interferon regulatory factor-2, and tumor necrosis factor alpha receptor-2 among others.
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
TLDR
At a given time point of the disease, the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient, suggesting that MS may be a disease with heterogeneous pathogenetic mechanisms.
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
TLDR
Increased numbers of IL-17 mRNA expressing MNC in MS are demonstrated with higher numbers in CSF than blood, and with the highest numbers in blood during clinical exacerbations.
Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy
Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis.
TLDR
It is shown that sCrry transgenic mice are either fully protected against EAE or develop significantly delayed clinical signs, indicating that complement activation may have an essential role in the pathogenesis of the disease and that complement-mediated events may occur early during the effector phase of EAE.
G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokine-Based Immune Deviation
TLDR
A novel activity of G-CSF is reported in experimental allergic encephalomyelitis, a murine model for multiple sclerosis, driven by Th1-oriented autoaggressive cells, and its potential application in the treatment of human autoimmune diseases such as multiple sclerosis is supported.
Cytokine accumulations in CSF of multiple sclerosis patients
TLDR
There was a high incidence of detectable IL-1β in patients with active MS compared with inactive MS or OND patients, and results raise the possibility that these cytokines may contribute to a variety of manifestations in MS and in other disease states.
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
TLDR
In vitro adhesion assay on tissue sections found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels, and therapies designed to interfere with α4βl integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.
Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.
TLDR
It is reported that IVIg treatment inhibited the active induction of both EAE and AA, and that this treatment did not affect the acquisition of resistance to reinduction of EAE, and the importance of the site of administration and schedule of treatment were studied.
...
1
2
3
4
5
...